Inhibition of stress-induced ligand-dependent egfr activation
AssigneeMax-Planck-Gesellschaft zur Foerderung der Wessenschaften. E.V.
InventorsAxel Ullrich, Oliver Fischer
Life of this patent
Estimating the term…
Abstract
The present invention relates to the inhibition of stress-induced receptor tyrosine kinase activity by inhibiting a ligand of said receptor tyrosine kinase, particularly an extracellular ligand.
Claims30
Use of an inhibitor of a receptor tyrosine kinase ligand for the manufacture of a medicament for the prevention or treatment of an at least partially therapy-resistant hyperproliferative disorder.
Use of an inhibitor of a receptor tyrosine kinase ligand for the manufacture of a medicament for increasing the efficacy of therapies against hyperproliferative disorders.
Use of an inhibitor of a receptor tyrosine kinase for the manufacture of a edicament for increasing the sensitivity of hyperproliferative disorders against irradiation and/or medicament treatment.
Use of an inhibitor of a receptor tyrosine kinase ligand for the manufacture of a medicament for the prevention or treatment of a hyperproliferative disorder which is caused by or associated with stress-induced activation of a receptor tyrosine kinase.
A pharmaceutical composition or kit comprising as active ingredients
- (a) an inhibitor of a receptor tyrosine kinase ligand which is an inhibitor of a metalloprotease capable of cleaving the receptor tyrosine kinase ligand or an inhibitor of regulatory steps upstream of the metalloprotease, and
- (b) a further medicament for the treatment of hyperproliferative disorders.
A method of preventing or treating an at least partially therapy-resistant hyperproliferative disorder comprising administrating an inhbitor of a receptor tyrosine kinase ligand to a subject in need thereof.
Dependencies are inferred from the claim text.